Glaxosmithkline Pharmaceuticals Ltd vs Roopa Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2120 as of 12 Jun 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 37.3 on March 2026 . This represents a CAGR of -9.55% over 6 yearsThe P/E Ratio of Roopa Industries Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 38682 crore on March 2026 . This represents a CAGR of 7.98% over 6 yearsThe Market Cap of Roopa Industries Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Roopa Industries Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Roopa Industries Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Roopa Industries Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 95.44 % on March 2026 . This represents a CAGR of -6.42% over 6 yearsThe Dividend Payout of Roopa Industries Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' in 1987 and was again changed to 'GlaxoSmithKline Pharmaceuticals Limited' dated October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is the Indian subsidiary of GSK plc, a UK-based, science-led global healthcare organisation focused on uniting science, technology and talent to get ahead of disease.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Roopa Industries Ltd

Roopa Industries Limited was incorporated 1985 as a Private Limited Company with the name 'Roopa Granites Private Limited', the name of the Company was changed to 'Roopa Granites Limited' in 1992 and further changed its name to M/s.
Roopa Industries in 1994.
The Company is engaged in manufacturing of Bulk drugs/Drug Intermediates. Roopa Industries Limited is a part of the TGV Group, a reputed conglomerate in India, which manufactures and exports Chloro Alkali Products, Castor Oil Derivatives, Fatty Acids and Water Treatment Chemicals to various countries.
The Company became a manufacturer of Neutraceuticals, Fine chemicals, Drug Intermediates and Bulk Drugs since 1998. The Company handled critical and risky processes and have dependable technical expertise for carrying out any labyrinthine hazardous manufacturing operations.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Roopa Industries Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Roopa Industries Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 35,925 Cr while Market cap of Roopa Industries Ltd is 37 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Roopa Industries Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Roopa Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Roopa Industries Ltd?

As of June 15, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2120.7. On the other hand, Roopa Industries Ltd stock price is INR ₹47.29.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Roopa Industries Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Roopa Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.